当前位置: 首页 >> 检索结果
1932. CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study.
作者: Matthew J Frank.;John H Baird.;Anne Marijn Kramer.;Hrishikesh K Srinagesh.;Shabnum Patel.;Annie Kathleen Brown.;Jean S Oak.;Sheren F Younes.;Yasodha Natkunam.;Mark P Hamilton.;Yi-Jiun Su.;Neha Agarwal.;Harshini Chinnasamy.;Emily Egeler.;Sharon Mavroukakis.;Steven A Feldman.;Bita Sahaf.;Crystal L Mackall.;Lori Muffly.;David B Miklos.; .
来源: Lancet. 2024年404卷10450期353-363页
Outcomes are poor for patients with large B-cell lymphoma who relapse after CD19-directed chimeric antigen receptor (CAR) T-cell therapy (CAR19). CD22 is a nearly universally expressed B-cell surface antigen and the efficacy of a CD22-directed CAR T-cell therapy (CAR22) in large B-cell lymphoma is unknown, which was what we aimed to examine in this study.
1934. Self-guided digital behavioural therapy versus active control for fibromyalgia (PROSPER-FM): a phase 3, multicentre, randomised controlled trial.
作者: R Michael Gendreau.;Lance M McCracken.;David A Williams.;Juan V Luciano.;Yifei Dai.;Nicolette Vega.;Zunera Ghalib.;Kristen Guthrie.;Allison C Kraus.;Michael J Rosenbluth.;Ben Vaughn.;Jennifer M Zomnir.;Dana Reddy.;Andrea L Chadwick.;Daniel J Clauw.;Lesley M Arnold.
来源: Lancet. 2024年404卷10450期364-374页
International guidelines have recommended cognitive behavioural therapy, including acceptance and commitment therapy (ACT), as it offers validated benefits for managing fibromyalgia; however, it is inaccessible to most patients. We aimed to evaluate the effect of a 12-week, self-guided, smartphone-delivered digital ACT programme on fibromyalgia management.
|